Questionable Drug Quality and Regulation The FDA has issued warnings about the dangers of using unapproved versions of weight-loss medications like semaglutide and tirzepatide, citing reports of adverse events affecting hundreds of patients
Stopping seven days prior was a risk factor for aspiration pneumonitis (odds ratio, 1.29), with higher risks seen for stopping five days and one day prior (odds ratios, 2.74 and 2.74, respectively)
Under its new policy, Blue Cross Blue Shield of Massachusetts said Thursday it will continue to cover the meds, known as GLP-1s, in its standard health benefits when theyre prescribed for diabetes but not for obesity
Mild swelling, redness, or tenderness in the treated area is normal and typically resolves within a few days
GLP-1 analogs are often evaluated alongside GIP, glucagon, or amylin activity depending on the product family and experimental design